» Articles » PMID: 26331622

TIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and Protects Tumor Cells from Apoptosis

Overview
Journal PLoS One
Date 2015 Sep 3
PMID 26331622
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Membrane-type 1 matrix metalloproteinase (MT1-MMP), a transmembrane proteinase with an extracellular catalytic domain and a short cytoplasmic tail, degrades a variety of extracellular matrix (ECM) components. In addition, MT1-MMP activates intracellular signaling through proteolysis-dependent and independent mechanisms. We have previously shown that binding of tissue inhibitor of metalloproteinases-2 (TIMP-2) to MT1-MMP controls cell proliferation and migration, as well as tumor growth in vivo by activating the Ras-extracellular signal regulated kinase-1 and -2 (ERK1/2) pathway through a mechanism that requires the cytoplasmic but not the proteolytic domain of MT1-MMP. Here we show that in MT1-MMP expressing cells TIMP-2 also induces rapid and sustained activation of AKT in a dose- and time-dependent manner and by a mechanism independent of the proteolytic activity of MT1-MMP. Fibroblast growth factor receptor-1 mediates TIMP-2 induction of ERK1/2 but not of AKT activation; however, Ras activation is necessary to transduce the TIMP-2-activated signal to both the ERK1/2 and AKT pathways. ERK1/2 and AKT activation by TIMP-2 binding to MT1-MMP protects tumor cells from apoptosis induced by serum starvation. Conversely, TIMP-2 upregulates apoptosis induced by three-dimensional type I collagen in epithelial cancer cells. Thus, TIMP-2 interaction with MT1-MMP provides tumor cells with either pro- or anti-apoptotic signaling depending on the extracellular environment and apoptotic stimulus.

Citing Articles

Mmp14-dependent remodeling of the pericellular-dermal collagen interface governs fibroblast survival.

Sabeh F, Li X, Olson A, Botvinick E, Kurup A, Gimenez L J Cell Biol. 2024; 223(9.

PMID: 38990714 PMC: 11244150. DOI: 10.1083/jcb.202312091.


MicroRNA 429 regulates MMPs expression by modulating TIMP2 expression in colon cancer cells and inflammatory colitis.

Han S, Mo J, Yun K, Chae S Genes Genomics. 2024; 46(7):763-774.

PMID: 38733517 DOI: 10.1007/s13258-024-01520-y.


The TIMP protein family: diverse roles in pathophysiology.

Coates-Park S, Rich J, Stetler-Stevenson W, Peeney D Am J Physiol Cell Physiol. 2024; 326(3):C917-C934.

PMID: 38284123 PMC: 11193487. DOI: 10.1152/ajpcell.00699.2023.


MT1-MMP as a Key Regulator of Metastasis.

Tanaka N, Sakamoto T Cells. 2023; 12(17).

PMID: 37681919 PMC: 10486781. DOI: 10.3390/cells12172187.


The Biology and Function of Tissue Inhibitor of Metalloproteinase 2 in the Lungs.

Costanzo L, Soto B, Meier R, Geraghty P Pulm Med. 2023; 2022:3632764.

PMID: 36624735 PMC: 9825218. DOI: 10.1155/2022/3632764.


References
1.
Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H . Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 1997; 57(10):2055-60. View

2.
Katz M, Amit I, Yarden Y . Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007; 1773(8):1161-76. PMC: 2758354. DOI: 10.1016/j.bbamcr.2007.01.002. View

3.
Olex A, Turkett W, Fetrow J, Loeser R . Integration of gene expression data with network-based analysis to identify signaling and metabolic pathways regulated during the development of osteoarthritis. Gene. 2014; 542(1):38-45. PMC: 4031746. DOI: 10.1016/j.gene.2014.03.022. View

4.
Baker E, Bergin F, Leaper D . Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg. 2000; 87(9):1215-21. DOI: 10.1046/j.1365-2168.2000.01531.x. View

5.
Hoegy S, Oh H, Corcoran M, Stetler-Stevenson W . Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem. 2000; 276(5):3203-14. DOI: 10.1074/jbc.M008157200. View